

[Fig. 1]

FIG. 1




MET Antibodies Work Flow

FIG. 2



[Fig. 3]

FIG. 3



[Fig. 4]

2

FIG. 4

PLATE 3				
Well name	Description	FACS Geom. Mean	MET BINDING ELISA ODA50nm	
Well_E01.fcs	negative control	103000	NA	
Well_F01.fcs	negative control	116000	NA	
Well_A01.fcs	positive control	83500	NA	
Well_B01.fcs	positive control	81800	NA	
Well_E08.fcs	hybridoma	61000	4.5319	
Well_D12.fcs	hybridoma	67200	4.3803	
Well_E02.fcs	hybridoma	69800	4.596	
Well_F04.fcs	hybridoma	77300	3.0801	
Well_B10.fcs	hybridoma	97700	0.0211	
Well_H06.fcs	hybridoma	97600	6.1209	
Well_F06.fcs	hybridoma	97800	-0.0005	
Well_G10.fcs	hybridoma	98800	0.0078	
Well_E07.fcs	hybridoma	98900	0.0011	
Well_H10.fcs	hybridoma	98500	1.7238	
Well_E06.fcs	hybridoma	99300	5.2925	
Well_F10.fcs	hybridoma	99700	0.0185	
Well_F07.fcs	hybridoma	99600	0.235	

[Fig. 5]







FIG. 6



[Fig. 7-1]

FIG. 7 Anti-Met antibodies species cross-reactivity

[Fig. 7-2]



[Fig. 8]

Sequences of top 9 murine clones. Two clones were duplicated giving 7 unique sequences

FIG. 8A

Light Chain		1	10	20	30	40	50	60	70	80	90	100	110	117	SEQ ID NO:
F5_F5_8a_I_ (1)	--	EVLAFTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	37								
F5a_F5_8a_I_ (1)	--	DIIVTSPKSGSGVGRVTLGSGAS	-----	ENVGI	YVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	38							
F5a_F5_8a_I_ (1)	--	GVVSGSPSLAVSGVNTVSGSGSGLYSGHQA	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	39									
F5a_F5_8a_I_ (1)	REU	QMTQSPASLVSGVGTITCRASENIYQ	-----	TLAMTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	40								
F5a_F5_8a_I_ (1)	--	QVLTQSPASLVSGVGTITCRASENIYQ	-----	TLAMTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	41								
F5a_F5_8a_I_ (1)	--	QVLTQSPASLVSGVGTITCRASENIYQ	-----	TLAMTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	42								
F5a_F5_8a_I_ (1)	--	QVLTQSPASLVSGVGTITCRASENIYQ	-----	TLAMTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	43								

HC F5aF5_8a_I_2-F5aF5_8a_I_2

LC F5aF5_8a_I_2-F5aF5_8a_I_2

FIG. 8B

Heavy Chain

Heavy Chain		1	10	20	30	40	50	60	70	80	90	100	110	131	SEQ ID NO:
F5_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	94								
F5a_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	95								
F5a_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	96								
F5a_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	97								
F5a_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	98								
F5a_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	99								
F5a_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	100								
F5a_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	101								
F5a_F5_8a_H_ (1)	---	QVQLSPTSLPGLPGASISCHSC	TIIVSGTMT	YLVNTQNGSGKLLIVYSSG	SVFSGSGSCTFTLISRVASDLGV	CPQGSNVPYTCGGCKLEIR	102								

HC F5aF5_8a_H_2-F5aF5_8a_H_2

LC F5aF5_8a_H_2-F5aF5_8a_H_2

[Fig. 9]

Fig. 9A







Fig. 9B




[Fig. 10]



[Fig. 11]



[Fig. 12]



[Fig. 13]

3

FIG. 13
HUMANIZED LIGHT CHAIN VARIABLE REGIONS

SEQ ID	NO: 1	50
P3D12 VL 45	QIVLTQSPAINASPGKVTLTTCASSSVTSNYLYNYQCKPGSSRLNIY	50
P3D12 VL-ven 46	QIVLTQSPATMSASPGKVTLSGASSSVTSNYLYNYQCKPGSSRLNIY	
P3D12 VL-fra 47	QIVLTQSPAILSLSPGERATLSGASSSVTSNYLYNYQCKPGSSRLNIY	
P3D12 VL-abb/sdr 48	QIVLTQSPATLSLSPGERATLSGASSSVTSNYLYNYQCKPGSSRLNIY	
P3D12 VL-cdr 49	QIVLTQSPATLSLSPGERATLSGASSSVTSNYLYNYQCKPGSSRLNIY	
	31	100
P3D12 VL 45	STSNLASGVPAEFSGSGSGTSTSTLTISGAEADAASYECHQMSYPPFTG	
P3D12 VL-ven 46	STSNLASGVPAEFSGSGSGTSTSTLTISRMFEDAASTCHQMSYPPFTG	
P3D12 VL-fra 47	STSNLASGVPAEFSGSGSGTSTSTLTISGLEADAASYECHQMSYPPFTG	
P3D12 VL-abb/sdr 48	STSNLASGVPAEFSGSGSGTSTSTLTISRLRPEDFASVFECHQMSYPPFTG	
P3D12 VL-cdr 49	STSNLASGVPAEFSGSGSGTSTSTLTISRLRPEDFASVFECHQMSYPPFTG	
	101	
P3D12 VL 45	SGTKLEIKR	
P3D12 VL-ven 46	SGTKLEIKR	
P3D12 VL-fra 47	SGTKLEIKR	
P3D12 VL-abb/sdr 48	SGTKLEIKR	
P3D12 VL-cdr 49	SGTKLEIKR	

[Fig. 14]

3

FIG. 14
HUMANIZED HEAVY CHAIN VARIABLE REGIONS

```

SEQ ID NO: 1 50
VLP3D12 VH 104 QVQLQSOGLAKPGASVKMSCKRASSYFTTSYMMHWVKQRFQGGLEWIGY
P3D12 VH-ven 105 QVQLQSOGLAEVKKPGASVIVSKKASGYTETSYMMHWVKQRFQGGLEWIGY
P3D12 VH-FLA 106 QVQLVQSGAEVAKPGASVKMSCKRASSYFTTSYMMHWVKQRFQGGLEWIGY
P3D12 VH-abb/sdr 107 QVQLVQSGAEVSKPGASVIVSKKASGYTETSYMMHWVKQRFQGGLEWIGY
P3D12 VH-cdr 108 QVQLVQSGAEVKKPGASVKVVELRASCYFTTSYMMHWVKQRFQGGLEWIGY

51 100
P3D12 VH 104 IKPSTDNTEYNQKFKKATLTADKSSSTAYMQLSLTSELSAVYYCARSY
P3D12 VH-ven 105 IKPSTDNTEYNQKFKGVTLTADKSTSTAYMQLSNLISEDTAVYYCARSY
P3D12 VH-FLA 106 IKPSTDNTEYNQKFKKATLTADKSTSTAYMQLSLRSEDTAVYYCARSY
P3D12 VH-abb/sdr 107 IKPSTDNTEYAKKFGGVTLTADKSTSTAYMBLSLRSEDTAVYYCARSY
P3D12 VH-cdr 108 IKPSTDNTEYNQKFKKATLTADKSTSTAYMQLSLRSEDTAVYYCARSY

101 119
P3D12 VH 104 GNYPIMDIWGQGTSTVYS
P3D12 VH-ven 105 GNYPIMDIWGQGTSTVYS
P3D12 VH-FLA 106 GNYPIMDIWGQGTITVYS
P3D12 VH-abb/sdr 107 GNYPIMDIWGQGTITVYS
P3D12 VH-cdr 108 GNYPIMDIWGQGTITVYS

```


[Fig. 16]









FIG. 16

[Fig. 17]



Antibody	hD12	Denosumab	hD12	Denosumab	hD12	Denosumab	hD12	Denosumab
Payload	VI	VI	II	II	VII	VII	IV	XI
IC50(ug/ml)	0.026	...	0.052	...	0.042	...	0.068	0.103

[Fig. 18-1]



[Fig. 18-2]

FIG. 18E

	Antibody	hD12	hD12	hD12	hD12	hD12	hD12
	Payload	VI	II	VIII	IV	XI	
SNU-1	Max %kill / IC50(μM)	19% / ---	47% / ---	38% / ---	3% / ---	52% / ---	
SNU-16	Max %kill / IC50(μM)	76% / 27.3	80% / 30.9	81% / 9.0	78% / 58.7	86% / 13.5	
SNU-620	Max %kill / IC50(μM)	84% / 338.4	90% / 174.8	89% / 363.5	81% / 326.6	80% / 405.9	
MKN-45	Max %kill / IC50(μM)	74% / 47.7	77% / 86.9	81% / 64.2	71% / 72.2	73% / 82.0	
	Ave DAR (HIC)	1.82	1.98	0.84	1.88	2.99	
	DAR 0% (HIC)	35.82%	23.25%	58.02%	23.95%	5.88%	
	Free Drug (RP)	1.61%	0.71%	1.89-1.98%	N/A	N/A	

[Fig. 19-1]

FIG. 19A




FIG. 19B




FIG. 19C





FIG. 19D



[Fig. 19-2]

FIG. 19E





FIG. 19F

	Antibody Payload	hD12 VI	hD12 II	hD12 VII	hD12 IV	hD12 XI
H441	Max %kill / IC50(μM)	58% / 1.3	68% / 3.8	63% / 2.1	43% / 38.5	54% / 8.0
H1373	Max %kill / IC50(μM)	47% / 16.7	68% / 35.6	75% / 42.66	35% / 19.7	68% / ----
H1573	Max %kill / IC50(μM)	16% / 2.0	50% / 8.7	47% / 49.5	4% / 14.4	29% / 6.2
H1975	Max %kill / IC50(μM)	64% / 111.8	81% / 311.1	94% / 33.8	50% / 174.3	82% / 622.9
SNU-5	Max %kill / IC50(μM)	81% / 17.1	83% / 22.4	94% / 5.9	76% / 30.5	77% / 22.3
Ave DAR (HIC):		1.62	1.96	0.84	1.89	2.99
DAR 0% (HIC):		35.82%	23.25%	58.02%	23.95%	5.88%
Free Drug (RP):		1.61%	0.71%	1.89-1.96%	N/A	N/A

[Fig. 20-1]

FIG. 20A



[Fig. 20-3]




FIG. 20C

[Fig. 20-4]




FIG. 20D

[Fig. 20-5]





FIG. 20E

[Fig. 20-6]



[Fig. 20-7]





FIG. 20G

[Fig. 21-1]



[Fig. 21-2]




FIG. 21C

[Fig. 21-3]






FIG. 21D

[Fig. 21-4]

FIG. 21E



[Fig. 23]



[Fig. 24]





FIG. 24B


Antibody	hD12	hD12	hD12	hD12	Denosumab
	T289C	V442C	V282C		
Payload	II	II	II	II	II
EC50(ug/ml)	0.011	0.023	0.034	0.049	0.238

[Fig. 25-1]

FIG. 25A




[Fig. 25-2]




[Fig. 25-3]

FIG. 25C



[Fig. 25-4]


FIG. 25D



[Fig. 25-5]

FIG. 25E

N87 hD12 Site Specific Samples
(MET Low)



[Fig. 25-6]

FIG. 25F

	Antibody	hD12	hD12	hD12	hD12	Denosumab
		T289C	V442C	V282C	Vc-PBD	Vc-PBD
	Payload	II	II	II	II	II
SNJ-1	Max %kill / IC50(μM)	91% / ---	81% / ---	84% / ---	33% / ---	42% / ---
SNJ-16	Max %kill / IC50(μM)	95% / 100.3	94% / 91.9	95% / 140.9	90% / 51.6	80% / ---
SNJ-620	Max %kill / IC50(μM)	99% / 122.9	99% / 116.3	99% / 123.7	98% / 155.1	5% / ---
MKN-45	Max %kill / IC50(μM)	99% / 34.9	99% / 46.6	99% / 54.5	96% / 72.9	36% / ---
N87	Max %kill / IC50(μM)	96% / 440.0	96% / 518.3	97% / 472.2	86% / 979.8	86% / ---
	DAR	2	2	2	---	---
	Ave DAR (HIC)	---	---	---	1.96	2.31
	DAR 0% (HIC)	---	---	---	23.25%	5.88%
	Free Drug (RP)	---	---	---	0.71%	0.43%
	Batch #:	SPADC3118.01	SPADC3117.01	SPADC3119.01	SG3249.019	SG3249.019

FIG. 25G

pM
50000
10000
2000
400
80
16
3.2
0.64

[Fig. 26]




FIG. 26B


	Antibody		hD12		hD12		hD12		hD12		Denosumab	
	Payload		T289C		V442C		V282C		Vc-PBB		Vc-PBB	
NBT	Max %/IC50 (nM)		90% / ...		90% / ...		92% / ...		71% / ...		71% / ...	
SNU-5	Max %/IC50 (nM)		94% / 5.1		88% / 13.5		93% / 4.5		98% / 9.8		72% / ...	
	DAR		2		2		2		...		...	
	Ave DAR (nM)		...		...		...		1.56		2.31	
	DAR (%) (nM)		...		...		...		28.25%		5.88%	
	Free Drug (%)		...		...		...		0.71%		0.43%	
	Batch #		SPAD3116-01/SPAD3117-01/SPAD3119-01		SPAD3119-01		SPAD3119-01		SPAD3119-01		SPAD3119-01	

FIG. 26C

pM
50000
10000
2000
400
80
16
3.2
0.64


[Fig. 27-1]

FIG. 27A




[Fig. 27-2]

FIG. 27B



[Fig. 27-3]

FIG. 27C



[Fig. 27-4]

FIG. 27D

µM
50000
10000
2000
400
80
16
3.2
0.64

FIG. 27E

	Antibody	hD12 T289C	hD12 V443C	hD12 V382C	hD12 Vc-PBD	Denosumab Vc-PBD
	Payload	II	II	II	II	II
H1373	Max %K ₈₈ / K250(µM)	98% / ---	98% / ---	97% / 65.0	77% / 17.9	72% / ---
H1573	Max %K ₈₈ / K250(µM)	69% / ---	88% / ---	91% / ---	69% / 18.9	52% / ---
H1975	Max %K ₈₈ / K250(µM)	98% / 23.9	97% / 27.8	98% / 41.5	67% / 49.2	78% / ---
	DAR	2	2	2	---	---
	Ave DAR (H ₂ O)	---	---	---	1.98	2.31
	DAR 0% (H ₂ O)	---	---	---	23.25%	5.88%
	Free Drug (p2)	---	---	---	0.71%	0.43%
	Batch #	SPAD03118.01	SPAD03117.01	SPAD03119.01	SC3249.019	SC3249.019

[Fig. 28-1]




FIG. 28A

[Fig. 28-2]






FIG. 28B

[Fig. 28-3]

FIG. 28C



[Fig. 30]




[Fig. 31]

FIG. 31

Test article	TS (hours)	AUC _{0-12h} (ng·h/mL)	CL _{CR} (mL/min/kg)	C _{0-12h} (ng/mL)
HD12-V282C-II 1 mg/kg	273.5 (11.3d)	3777	0.0007	32.9
HD12-T289C-II 1 mg/kg	431.6 (1.8d)	3352	0.0007	32.9
HD12-V442C-II 1 mg/kg	337.0 (13.6)	3712	0.0007	32.1

[Fig. 32]



[Fig. 33-1]


FIG. 33B



Model ID	H-Score
GA3121	295

FIG. 33A

GA3121



[Fig. 33-2]

